One of the most intriguing aspects of multiple sclerosis (MS) is that during childbearing years, women are more likely to develop MS than men, but are also less likely to experience progression to disability. 1 In fact, a number of critical periods of development have been identified, including the prenatal environment, puberty, pregnancy, and reproductive aging that appear to regulate MS risk and course. The marked hormonal transitions during each of these periods implicate hormonal regulation of inflammatory activity and/or neurodegeneration in MS. Our ACTRIMS 2017 Scientific Session titled "Hormones and MS: Risk Factors, Biomarkers, and Therapeutic Targets" highlighted some of the transitions (puberty) and hormones (androgens), as well as the modifying effect of sex chromosomes on MS risk and course. Three speakers presented data and scientific perspectives that are also included as manuscripts in this issue of the MS journal.
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Dr Rhonda Voskuhl first reviewed what is known about the contribution of the XX (female) and XY (male) sex chromosome complement to sex differences in experimental autoimmune encephalomyelitis (EAE) in SJL mice. Her laboratory has been using the "four core genotypes" model, which allows separation of sex differences due to sex chromosome complement, endogenous gonadal hormones, or combinations of the two. It was established by deletion of the testis determining gene, Sry, from the Y chromosome (designated XY−), combined with insertion of a Sry transgene onto an autosome. 2 Thus, XX and XY− mice with testes and XX and XY− mice with ovaries are generated. Data from the Voskuhl laboratory show that the XX sex chromosome complement directly influences immune responsiveness in favor of pro-inflammatory, diseasepromoting activities, 3 while the XY complement confers more severe clinical and neuropathological EAE. 4 Although incompletely understood at this time, the findings are consistent with increased MS susceptibility and higher levels of pro-inflammatory immune responses in women, and more progressive disease in men. Dr Voskuhl also discussed additional effects of sex chromosomes and epigenetic factors with potential to influence MS risk and disease activity, such as X-inactivation (inactivation of one X chromosome in female blastocysts), parental imprinting (expression of genes in a parent-of-origin fashion), and tissue-specific differences in expression of genes on the X chromosome. Of special note, genes expressed on the X and Y chromosomes are rarely assessed in genome-wide expression studies, despite the potential to lead to new insights into MS risk and disease phenotypes. 5, 6 Focusing on the pubertal period of development, Dr Emmanuelle Waubant reviewed data supporting puberty as a period that ushers in an increased risk of MS, particularly in girls. Earlier puberty represents both a risk factor for MS 7 and for earlier onset of MS symptoms. [8] [9] [10] Puberty may represent a proxy for earlier risk exposures (such as adiposity or shared genes) that influence both downstream immune signaling and pubertal age. But hormonal changes that occur at puberty also influence immune pathways, and could thereby stimulate immune activity. 11 Earlier age at puberty has also been associated with earlier age of MS onset in boys, 12 but more extensive study is needed.
Observations of clinical disease during and after pregnancy, while not reviewed in our ACTRIMS session, are the bedrock of studies focused on hormones and sex differences in MS. During pregnancy, 13, 14 there is a well-established protective effect on MS relapses, followed by an increased relapse risk post-partum for up to 30% women. 15, 16 Although the underlying mechanisms have not been clearly elucidated, the traditional explanation is that peripheral immunity is biased during pregnancy in favor of anti-inflammatory Th2-like activities and against pathogenic effector Th1 cells and their functions. [17] [18] [19] [20] Additional findings indicate expansion of functional capacity in several regulatory cell types during pregnancy, including classical foxP3+ regulatory CD4+ T cells, CD8+ T cells, regulatory B cells, CD56hi NK cells, and antiinflammatory, type 2 myeloid cells. 17, 18, 21, 22 However, the mechanisms are likely more complicated, and may reflect attempts to balance maternal tolerance for a semi-allogeneic fetus with immune protection against infectious pathogens and other antigenic challenges, in both mother and fetus. Achievement of this remarkable balance results in gradual control of maternal autoimmunity and clinical disease that accumulates to a peak in the third trimester. In addition to immune modulation, clinical benefits may also reflect reductions in central nervous system (CNS) inflammation and perhaps, more direct neuroprotective hormone activities.
Several explanations for the increased risk for postpartum relapses have been offered. First, there is a rebound of pro-inflammatory cell types and functions after delivery 17, 23 likely due to removal of fetus and the hormone-rich placenta. Simultaneously, multiple mechanisms are set in play to allow milk production, lactation, and mother-baby bonding. Of special note, data are accumulating to support a mitigating effect of breastfeeding on the post-partum risk for relapses, especially in the absence of supplemental feeding (i.e. exclusive breastfeeding). [24] [25] [26] Hormonal signaling during breastfeeding may reflect metabolic demands placed on the mother, with potential to modulate immune activity and relapse susceptibility, 27, 28 but the mechanisms remain to be elucidated. With respect to management of pregnancy in MS, recent advances, allowed in part by concerted efforts of established drug-and MS-specific registries, have provided increasing evidence that injectable therapies are likely not associated with any clear adverse fetal outcomes in pregnancy. In recent case series, an increased risk of intra-and post-partum relapses has also been reported in neuromyelitis optica (NMO), along with an apparent increased risk of preeclampsia and pregnancy loss.
Finally, coincident with reproductive aging, MS appears to worsen in women and possibly in men. Initial observational studies have suggested an increase in the rate of disability accumulation in women after menopause, 29 as well as a narrowing of sex differences in disability progression in individuals with MS onset after the age of 50 years. 30 The timing of menopause is notably protracted, and other approaches to evaluating the impact of ovarian aging on MS course have focused on levels of the serum marker anti-Mullerian hormone (AMH). To date, reports of an association between AMH levels and MS risk are conflicting, 31, 32 but AMH levels were negatively correlated with higher disease activity in both studies. The association between worsening disability progression and reproductive aging has not clearly implicated hormonal modulation of immune function and neural repair mechanisms, as opposed to hormonal effects on other organs (e.g. on bladder function). In addition, accelerated ovarian aging may represent just one marker of other exposures affecting MS. For example, AMH levels vary with experiential factors like smoking and younger age at menarche, or with indicators of more widespread accelerated aging (e.g. accelerated telomere shortening). 33 Focusing on mechanisms by which specific hormones may influence MS risk and course, Dr Tanuja Chitnis discussed the role of testosterone in MS, mostly in men. Testosterone has been consistently reported to exhibit anti-inflammatory, Th2-like activities in the periphery and in the CNS, and shows neuroprotective properties in animal models. 12, 19 Reduced testosterone levels including low androgen levels in utero 12 have been implicated as risk factors for disability and development of MS in men. 12, 34 Low testosterone levels may also result from chronic disease states. In any case, less control of proinflammatory autoimmunity and increases in measures of disability and cognitive dysfunction are likely consequences of reduced testosterone. Additional study is needed to more clearly define the role of testosterone in MS, and to identify mechanisms underlying more progressive disease in men.
Several therapeutic approaches have been proposed using exogenous hormones. Overall, observational studies of exogenous oral contraceptives (OCs, administered for varying durations at varying formulations across epochs) have mostly but not always 35 suggested protective or 36-38 neutral 39,40 associations with MS risk and relapse risk. [41] [42] [43] Two recent interventional studies suggest a beneficial effect of either the OC ethinylestradiol 40 μg and desogestrel 125 μg 44 or the pregnancy hormone estriol, on inflammatory activity when given as add-ons to platform injectable therapies. 45 The major limitation of this therapeutic approach is the cumulative risk accumulated with long-term use of exogenous estrogens. Recent data suggested better physical quality of life (QOL) at menopause in women with MS who used exogenous estrogens. However, it was not clear whether hormone therapy use improved physical QOL or reflected the fact that women with better physical QOL were likely to receive age-appropriate medical care, including hormone therapy. 46 More targeted selective estrogen receptor modulators have been identified in screens of FDA-approved compounds as capable of protecting oligodendrocyte viability in inflammatory conditions and promoting oligodendrocyte differentiation, possibility leading to remyelination. 47, 48 Less is known about exogenous treatment with testosterone or progesterone. A phase-I clinical trial reported improvements in cognitive function and brain atrophy in men after treatment with testosterone gel. 49 Progestins, including progesterone, exhibit anti-inflammatory activities and neuroprotective properties 50 but did not prevent post-partum relapses in MS. 51 The discussion after the session raised important questions about the state of current knowledge of sexual dimorphism in MS. First, the field has likely been limited by its treatment of hormones as binary, static levels rather than continuously fluctuating in response to internal and external stimuli. Another limitation is mechanistic in nature and reflects pleotropic effects of hormones on multiple cell types, including those involved in myelin destruction (immune cells), repair (oligodendrocytes, oligodendrocyte progenitor cells, and neural stem cells), and neuronal survival. Finally, over the past century, there has been a disproportionate increase in the rate of MS in young women of childbearing age, 52 paralleling increasing westernization and urbanization, 53 suggesting sex-specific plasticity in response to changing exposures, including environmental exposures and reproductive choices. 54 Nevertheless, the study of gender and hormones is rich with potential for new insights into MS pathogenesis, and thus, new approaches to treatment in the future.
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